Carvykti
Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.
Legend, Janssen Will Invest $150M to Expand Carvykti Manufacturing in Europe
The firms expect that by expanding manufacturing capacity they can double the sales volume of Carvykti from 10,000 doses in 2025 to 20,000 doses in 2027.
J&J Reports Strong Uptake of Carvykti and Rybrevant in Q4
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.
The iMMagine-1 data suggest anito-cel could have a differentiated safety and efficacy profile compared to available BCMA-directed therapies.
The drugmaker met increased demand following approval of Carvykti in earlier lines of therapy with expanded production at US and European facilities.